Pharmacoeconomic evaluation of insulin aspart and glargine in type 1 and 2 diabetes mellitus in Iran
ConclusionInsulin analogs, IAsp and IGla, are cost-effective for type 1 diabetes versus human insulins, RI and NPH. For type 2 diabetes, IAsp is not cost-effective when compared with RI. For IGla versus NPH, however, the incremental cost-effectiveness ratio seems to be within the accepted thresholds.
Source: Journal of Diabetes and Metabolic Disorders - Category: Endocrinology Source Type: research
More News: Diabetes | Diabetes Mellitus | Diabetes Type 1 | Diabetes Type 2 | Endocrinology | Insulin | Iran Health | Lantus | Middle East Health | Study